Table 1.
Baseline Demographic and Clinical Characteristics of the Study Population
| Characteristic | Population (N = 72) |
|---|---|
| Age (years), mean ± SD | 63.3 ± 9.5 |
| Female sex, n (%) | 37 (51.3) |
|
Ethnicity White, n (%) Black, n (%) Other, n (%) |
62 (86.1) 8 (11.1) 2 (2.8) |
| Body mass index (kg/m2), median [25th–75th percentile] | 29.0 [26.1–32.8] |
| eGFR (ml/min/1.73m2), mean ± SD | 71.7 ± 16.0 |
| Diabetes Type 1, n (%) | 0 (0) |
| Diabetes Type 2, n (%) | 19 (26.4) |
| Electrocardiography | |
| Sinus rhythm at baseline, n (%) | 65 (90.3) |
| Office heart rate prior to procedure (BPM), median [25th–75th percentile] | 68.5 [58–8–77.3] |
| Office blood pressure measurements | |
| Office SBP (mmHg), mean ± SD | 169.2 ± 21.2 |
| Office DBP (mmHg), mean ± SD | 93.0 ± 14.1 |
| Isolated Systolic Hypertension, n (%) | 27 (37.5) |
| Ambulatory blood pressure measurements | |
| Daytime ambulatory SBP (mmHg), mean ± SD | 146.1 ± 17.4 |
| Daytime ambulatory DBP (mmHg), mean ± SD | 83.7 ± 12.2 |
| 24-h ambulatory SBP (mmHg), mean ± SD | 143.2 ± 16.4 |
| 24-h ambulatory DBP (mmHg), mean ± SD | 81.2 ± 11.5 |
| Nighttime ambulatory SBP (mmHg), mean ± SD | 134.0 ± 17.7 |
| Nighttime ambulatory DBP (mmHg), mean ± SD | 74.8 ± 12.7 |
| Number of antihypertensive medications at screening | |
| Total number of antihypertensive medications at screening, median [25th–75th percentile] | 3.0 [3.0–4.0] |
| 0* | 2 (2.8) |
| 1 | 2 (2.8) |
| 2 | 9 (12.5) |
| 3 | 27 (37.5) |
| 4 | 18 (25.0) |
| 5 | 10 (13.9) |
| 6 | 4 (5.6) |
| Defined Daily Dose (DDD) at screening, mean ± SD | 4.9 ± 2.7 |
| Antihypertensive load index at screening, mean ± SD | 2.1 ± 1.1 |
| Types of antihypertensive medication at screening within study population | |
| Angiotensin-converting enzyme inhibitor, n (%) | 16 (22.2) |
| Angiotensin receptor blocker, n (%) | 47 (65.3) |
| Direct renin inhibitor, n (%) | 0 (0) |
| Calcium Channel Blocker, n (%) | 48 (66.7) |
| Thiazide Diuretic, n (%) | 55 (76.4) |
| Loop Diuretic, n (%) | 3 (4.2) |
| Aldosterone antagonist, n (%) | 10 (13.9) |
| Alpha-1 receptor blocker, n (%) | 19 (26.4) |
| Beta Blocker, n (%) | 49 (68.1) |
| Centrally acting agent, n (%) | 0 (0) |
eGFR indicates estimated glomerular filtration rate, SBP systolic blood pressure, DBP diastolic blood pressure
*Two patients were drug intolerant